Garcia-Dominguez Maria A, Kipkorir Vincent, Srichawla Bahadar S
Department of Neurology, University of Massachusetts Chan Medical School, MA, USA.
Department of Medicine, University of Nairobi, Nairobi, Kenya.
Ann Med Surg (Lond). 2024 Jan 3;86(2):720-725. doi: 10.1097/MS9.0000000000001676. eCollection 2024 Feb.
To analyze the symptoms and severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (pwMS) on disease-modifying therapies using data from the COVID-19 in multiple sclerosis (MS) Global Data Sharing Initiative dataset.
The open-access COVID-19 in MS Global Data Sharing Initiative dataset was obtained through credentialed access using PhysioNet. The variables analyzed included BMI, symptoms of COVID-19, age, current use of disease-modifying therapy (DMT), efficacy of DMT, comorbidities, hospitalization status, and type of MS. A linear regression analysis was completed. Data analysis and visualization were completed using STATA , R-Studio , Python and its associated libraries, including NumPy, Pandas, and Matplotlib.
A total of 1141 participants were included in the analysis. 904 women and 237 men were diagnosed with MS. Among the pwMS included in the study; 208 (19.54%) had a suspected infection with COVID-19 and only 49 (5.25%) were confirmed. Any COVID-19 symptom was present in 360 individuals. The commonly reported DMT agents included dimethyl fumarate (12.71%) and fingolimod (10.17%). 101 in total (8.85%) reported not using any DMT. Factors associated with hospitalization and/or admission to the ICU included having any comorbidity (0.01), neuromuscular disorder (0.046), hypertension (0.005), chronic kidney disease (0.001), and immunodeficiency (0.003). The type of MS, the duration of the disease, and high-efficacy DMT therapy did not have a statistically significant influence on hospitalization.
This study underscores the importance of comorbidities, especially neuromuscular disorders, hypertension, chronic kidney disease, and immunodeficiencies, as possible prognostic indicators for worse outcomes of COVID-19 in pwMS. On the contrary, the type of MS, the duration of the disease, and the efficacy of disease-modifying therapy did not significantly affect the severity of the symptoms of COVID-19 in this cohort.
利用来自多发性硬化症（MS）患者中2019冠状病毒病（COVID-19）全球数据共享倡议数据集的数据，分析接受疾病修饰治疗的多发性硬化症患者（pwMS）中COVID-19的症状和严重程度。
通过使用PhysioNet的认证访问获得开放获取的MS中COVID-19全球数据共享倡议数据集。分析的变量包括体重指数（BMI）、COVID-19症状、年龄、当前疾病修饰治疗（DMT）的使用情况、DMT的疗效、合并症、住院状态和MS类型。完成了线性回归分析。使用STATA、R-Studio、Python及其相关库（包括NumPy、Pandas和Matplotlib）进行数据分析和可视化。
共有1141名参与者纳入分析。904名女性和237名男性被诊断为MS。在纳入研究的pwMS中；208人（19.54%）疑似感染COVID-19，仅49人（5.25%）确诊。360人出现任何COVID-19症状。常见的DMT药物包括富马酸二甲酯（12.71%）和芬戈莫德（10.17%）。共有101人（8.85%）报告未使用任何DMT。与住院和/或入住重症监护病房相关的因素包括有任何合并症（0.01）、神经肌肉疾病（0.046）、高血压（0.005）、慢性肾病（0.001）和免疫缺陷（0.003）。MS类型、疾病持续时间和高效DMT治疗对住院没有统计学上的显著影响。
本研究强调了合并症的重要性，尤其是神经肌肉疾病、高血压、慢性肾病和免疫缺陷，作为pwMS中COVID-19预后较差的可能预测指标。相反，MS类型、疾病持续时间和疾病修饰治疗的疗效在该队列中并未显著影响COVID-
